Global Age Related Macular Degeneration Treatment Market Size By Type (Lucentis, Eylea), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Age-Related Macular Degeneration (AMD) Treatment Market was valued at USD 11.6 billion in 2023 and is projected to reach USD 23.4 billion by 2031, expanding at a CAGR of 9.1% during the forecast period from 2023 to 2031. The rising geriatric population, increasing prevalence of AMD, and growing access to innovative biologics and gene therapies are key growth accelerators. With advancements in diagnostic imaging, early detection and timely intervention have improved, propelling demand for both wet and dry AMD treatments. Regulatory support and increased research funding for retinal diseases also contribute to market momentum.

Drivers:

1. Aging Global Population:

The incidence of AMD escalates with age. As populations in developed and emerging markets age rapidly, particularly those above 60 years, the risk of AMD rises, leading to increased demand for effective treatments.

2. Innovations in Biologics and Gene Therapy:

The introduction of anti-VEGF therapies has revolutionized wet AMD treatment. Emerging gene therapies and long-acting injectables are extending dosing intervals, reducing treatment burden, and improving patient adherence.

3. Improved Diagnostic Capabilities:

Technological advancements in optical coherence tomography (OCT) and fundus autofluorescence imaging are facilitating early-stage detection, driving timely therapeutic interventions and better prognoses.

Restraints:

1. High Treatment Costs:

Advanced therapies, including biologics and intravitreal injections, are costly, often requiring frequent administration. This limits accessibility, especially in low-income regions with inadequate healthcare infrastructure.

2. Limited Efficacy in Dry AMD:

Despite the dominance of anti-VEGF therapy in wet AMD, treatment options for dry AMD remain limited. The lack of approved therapies for geographic atrophy continues to hinder comprehensive market growth.

Opportunity:

1. Pipeline Expansion and R&D Investments:

Numerous pharmaceutical companies are investing heavily in AMD research, with several promising candidates in Phase III trials. Success in these trials could significantly reshape the treatment landscape, particularly for dry AMD.

2. Market Penetration in Emerging Economies:

With improving healthcare access in Asia-Pacific, Latin America, and the Middle East, market players have the opportunity to expand AMD treatment availability, especially as governments prioritize eldercare and chronic disease management.

Market by System Type Insights:

Wet AMD Treatments led the market in 2023, primarily due to the widespread use of anti-VEGF injections like ranibizumab and aflibercept. This segment is expected to continue its dominance, driven by next-generation biologics and biosimilars. Conversely, Dry AMD Treatments, including complement inhibitors and antioxidant therapies, are gaining traction with ongoing FDA approvals, particularly in the U.S.

Market by End-use Insights:

Hospitals and Ophthalmology Clinics held the largest market share in 2023, accounting for over 60% of global revenues. The increasing number of eye care centers, coupled with rising referrals and surgical procedures, supports this segment’s dominance. Homecare settings are expected to grow rapidly as tele-ophthalmology and remote disease monitoring tools evolve.

Market by Regional Insights:

North America remained the largest regional market in 2023, owing to advanced healthcare systems, high awareness, and robust reimbursement frameworks. However, Asia-Pacific is expected to witness the fastest CAGR, supported by a surge in geriatric population, expanding healthcare infrastructure, and increased screening initiatives in countries like China and Japan.

Competitive Scenario:

Key players in the Global Age-Related Macular Degeneration Treatment Market include:

Genentech (Roche)

Regeneron Pharmaceuticals

Novartis AG

Bayer AG

Kodiak Sciences

Apellis Pharmaceuticals

Allergan (AbbVie Inc.)

Iveric Bio (acquired by Astellas)

Graybug Vision

Ocugen Inc.

These companies focus on innovation through clinical trials, FDA approvals, strategic collaborations, and regional market expansions.

Scope of Work – Global Age-Related Macular Degeneration Treatment Market

Key Market Developments:

2023: FDA approved Syfovre™ (pegcetacoplan) by Apellis for geographic atrophy, marking a milestone in dry AMD treatment.

2024: Regeneron initiated Phase III trials for high-dose aflibercept to enhance durability of wet AMD therapy.

2025: Genentech’s Port Delivery System gained traction as a refillable anti-VEGF implant, reducing injection frequency for wet AMD patients.

FAQs:

1) What is the current market size of the Global Age-Related Macular Degeneration Treatment Market?

The market was valued at USD 11.6 billion in 2023.

2) What is the major growth driver of the Global Age-Related Macular Degeneration Treatment Market?

The rising geriatric population and advancements in biologic therapies are key growth drivers.

3) Which is the largest region during the forecast period in the Global Age-Related Macular Degeneration Treatment Market?

North America is projected to remain the largest region throughout the forecast period.

4) Which segment accounted for the largest market share in the Global Age-Related Macular Degeneration Treatment Market?

Wet AMD treatment segment led the market in 2023.

5) Who are the key market players in the Global Age-Related Macular Degeneration Treatment Market?

Genentech, Regeneron, Novartis, Bayer, and Apellis Pharmaceuticals are among the key players.